Telomerase peptide cancer vaccine (Genovax)

N/A

Report date: 2024/11/02 20:00:07

Base Information

Drug NameTelomerase peptide cancer vaccine (Genovax)
Drug Alias Name端粒酶肽肿瘤疫苗 - Genovax端粒酶肽癌疫苗 - GenovaxGX-301
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionCD4-positive T-lymphocytes stimulantsCD8-positive T-Lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalySpain
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenovax
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLaboratoires Leurquin MediolanumMediolanum Farmaceutici Spa
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A